

APTEVO THERAPEUTICS INC.  
2401 4th Avenue, Suite 1050  
Seattle, WA 98121

December 17, 2020

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

Attention: Mr. Jeffrey Gabor

**Re:           Aptevo Therapeutics Inc.  
              Registration Statement on Form S-3  
              File No. 333-251318**

Dear Mr. Gabor:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-251318) of Aptevo Therapeutics Inc. (the "Registration Statement"). We respectfully request that the Registration Statement become effective as of 4:05 p.m., Eastern Time, on December 18, 2020, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Morgan, Lewis & Bockius LLP, by calling Sean M. Donahue at (202) 538-3557.

*intentionally left blank*

*[Remainder of page*

---

Very truly yours,

Aptevo Therapeutics Inc.

By: /s/ Marvin L. White  
Marvin L. White  
President and Chief Executive Officer

CC: Heather Boussios, Aptevo Therapeutics Inc.  
Daphne Taylor, Aptevo Therapeutics Inc.  
Sean M. Donahue, Esq., Morgan, Lewis & Bockius LLP

*Request for Acceleration of Effectiveness of Registration Statement*

*[Signature Page to*